News, Events, Webinars | Julius Clinical

P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence

500+ person global organization spans 25+ countries with operations across North America, Europe, Africa, Latin America, and Asia-Pacific

News

Julius Clinical Welcomes Bassem Saleh as Chief Executive Officer

Zeist, The Netherlands – September 23, 2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic diseases, is pleased to announce the appointment of Bassem Saleh ...

Cardio-Metabolic and Renal Diseases, Neurological diseases, Infectious Diseases & Vaccines, RSV, Real-World Evidence

Julius Clinical Expands CNS and Cardiometabolic Capabilities with Post-Merger Growth and New Operations in Spain and Germany

Zeist, The Netherlands – 14.05.2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key th...

Whitepaper: Risk-Based Quality Management (RBQM)

📄 About This Document Learn how Risk-Based Quality Management (RBQM) can enhance the quality, efficiency, and oversight of clinical trials. This one-pager outlines the key principles of RBQM, its core components, and insights from a case study...

Articles
MASH (NASH)

Is MASH the Silent Disease Everyone Is Talking About? Expert Insights on Awareness, Diagnosis, and Treatment

Metabolic dysfunction-associated steatohepatitis, or MASH, is gaining attention across the medical community, but for many patients it remains a largely silent disease. Closely linked with obesity, type 2 diabetes and other cardiometabolic risk fa...

Articles
Type 2 Diabetes

Julius Clinical spoke to obesity expert Professor Liesbeth van Rossum about the multi-factorial, complex and often misunderstood disease and what the future holds

15 April 2025, The NetherlandsJulius Clinical’s Scientific Officer, Associate Professor Manuel Castro Cabezas, interviewed Professor Liesbeth van Rossum, internist-endocrinologist and professor in the field of obesity at the Erasmus MC, Univ...

MASH (NASH)

How hospital networks can optimise patient care, knowledge sharing and trial recruitment: a case study from the Dutch Thyroid Network

15 May 2025, The NetherlandsJulius Clinical’s Scientific Officer, practising internist, and founding member of the Dutch Thyroid Network (Schildkliernetwerk - Home), Dr Manuel Castro Cabezas, was delighted to sit down with Dr Marco Medici, a...

Neurological diseases, Infectious Diseases & Vaccines, RSV, Real-World Evidence

Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities

Zeist, Netherlands, May 14, 2025– Julius Clinical, a leading full-service Contract Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georg...

News
Alzheimer's

Recruitment milestone achieved in important Phase II study in Alzheimer’s Disease

Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer's Disease....

Cardio-Metabolic and Renal Diseases, MASH (NASH), Chronic Kidney Disease

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis

A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...